drug
as of 2026-07-01GWP42003 : GWP42004 (40:1)
at a glance
small molecule
Pre-approval / investigational in the US
Developed by GW Research Ltd
1 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
1
Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine
NCT01491490Phase 2Terminated
KOLs & investigators
6
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
indication
indication
indication